Skip to main content

More Lab-Made Nucleotides

Artificial bases that act like the real deal can be designed to bind specifically to tumor cells.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

PIXABAY, SKEEZESynthetic biologists have created two artificial nucleotide bases that pair up with one another and, unlike previous iterations of lab-made DNA, can incorporate into genetic sequences to form a properly structured double helix. The team has also used these artificial nucleotides to engineer genetic sequences that stick to cancerous, but not normal, cells.

“This is neat because they evolved selective binders to cancer cells,” Floyd Romesberg of the Scripps Research Institute in La Jolla, California, told New Scientist. “If you can selectively bind to cancer cells, you can imagine selectively killing them.”

Steven Benner of the Foundation for Applied Molecular Evolution in Gainesville, Florida, and colleagues expanded the genetic alphabet with two bases, called Z and P. In one paper, published May 11 in the Journal of the American Chemical Society, the team provided structural evidence that multiple adjacent pairs of Z:P could form a normal geometric configuration.

Then, in a second paper published May 12 with additional colleagues, Benner created a library of genetic sequences with a random string of nucleotides that included the Z and P ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile

Related Topics

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo